Sphingolipid metabolic pathway impacts thiazide diuretics blood pressure response

Insights from genomics, metabolomics, and lipidomics

Mohamed H. Shahin, Yan Gong, Reginald F. Frye, Daniel M. Rotroff, Amber L. Beitelshees, Rebecca A. Baillie, Arlene B. Chapman, John G. Gums, Stephen T Turner, Eric Boerwinkle, Alison Motsinger-Reif, Oliver Fiehn, Rhonda M. Cooper-DeHoff, Xianlin Han, Rima Kaddurah-Daouk, Julie A. Johnson

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background--Although hydrochlorothiazide (HCTZ) is a well-established first-line antihypertensive in the United States, < 50% of HCTZ treated patients achieve blood pressure (BP) control. Thus, identifying biomarkers that could predict the BP response to HCTZ is critically important. In this study, we utilized metabolomics, genomics, and lipidomics to identify novel pathways and biomarkers associated with HCTZ BP response. Methods and Results--First, we conducted a pathway analysis for 13 metabolites we recently identified to be significantly associated with HCTZ BP response. From this analysis, we found the sphingolipid metabolic pathway as the most significant pathway (P=5.8E-05). Testing 78 variants, within 14 genes involved in the sphingolipid metabolic canonical pathway, with the BP response to HCTZ identified variant rs6078905, within the SPTLC3 gene, as a novel biomarker significantly associated with the BP response to HCTZ in whites (n=228). We found that rs6078905 C-allele carriers had a better BP response to HCTZ versus noncarriers (ΔSBP/ΔDBP: -11.4/-6.9 versus -6.8/-3.5 mm Hg; ΔSBP P=6.7E-04; ΔDBP P=4.8E-04). Additionally, in blacks (n=148), we found genetic signals in the SPTLC3 genomic region significantly associated with the BP response to HCTZ (P < 0.05). Last, we observed that rs6078905 significantly affects the baseline level of 4 sphingomyelins (N24:2, N24:3, N16:1, and N22:1; false discovery rate < 0.05), from which N24:2 sphingomyelin has a significant correlation with both HCTZ DBP-response (r =-0.42; P=7E-03) and SBP-response (r=-0.36; P=2E-02). Conclusions--This study provides insight into potential pharmacometabolomic and genetic mechanisms underlying HCTZ BP response and suggests that SPTLC3 is a potential determinant of the BP response to HCTZ.

Original languageEnglish (US)
Article numbere006656
JournalJournal of the American Heart Association
Volume7
Issue number1
DOIs
StatePublished - Jan 1 2018

Fingerprint

Sodium Chloride Symporter Inhibitors
Sphingolipids
Hydrochlorothiazide
Metabolomics
Genomics
Metabolic Networks and Pathways
Blood Pressure
Sphingomyelins
Biomarkers
Antihypertensive Agents
Genes

Keywords

  • Blood pressure
  • Lipid metabolites
  • Metabolomics
  • Pharmacogenetics
  • Thiazide diuretics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Sphingolipid metabolic pathway impacts thiazide diuretics blood pressure response : Insights from genomics, metabolomics, and lipidomics. / Shahin, Mohamed H.; Gong, Yan; Frye, Reginald F.; Rotroff, Daniel M.; Beitelshees, Amber L.; Baillie, Rebecca A.; Chapman, Arlene B.; Gums, John G.; Turner, Stephen T; Boerwinkle, Eric; Motsinger-Reif, Alison; Fiehn, Oliver; Cooper-DeHoff, Rhonda M.; Han, Xianlin; Kaddurah-Daouk, Rima; Johnson, Julie A.

In: Journal of the American Heart Association, Vol. 7, No. 1, e006656, 01.01.2018.

Research output: Contribution to journalArticle

Shahin, MH, Gong, Y, Frye, RF, Rotroff, DM, Beitelshees, AL, Baillie, RA, Chapman, AB, Gums, JG, Turner, ST, Boerwinkle, E, Motsinger-Reif, A, Fiehn, O, Cooper-DeHoff, RM, Han, X, Kaddurah-Daouk, R & Johnson, JA 2018, 'Sphingolipid metabolic pathway impacts thiazide diuretics blood pressure response: Insights from genomics, metabolomics, and lipidomics', Journal of the American Heart Association, vol. 7, no. 1, e006656. https://doi.org/10.1161/JAHA.117.006656
Shahin, Mohamed H. ; Gong, Yan ; Frye, Reginald F. ; Rotroff, Daniel M. ; Beitelshees, Amber L. ; Baillie, Rebecca A. ; Chapman, Arlene B. ; Gums, John G. ; Turner, Stephen T ; Boerwinkle, Eric ; Motsinger-Reif, Alison ; Fiehn, Oliver ; Cooper-DeHoff, Rhonda M. ; Han, Xianlin ; Kaddurah-Daouk, Rima ; Johnson, Julie A. / Sphingolipid metabolic pathway impacts thiazide diuretics blood pressure response : Insights from genomics, metabolomics, and lipidomics. In: Journal of the American Heart Association. 2018 ; Vol. 7, No. 1.
@article{cfcbfe266b5b4b57aa5073caa9ec489c,
title = "Sphingolipid metabolic pathway impacts thiazide diuretics blood pressure response: Insights from genomics, metabolomics, and lipidomics",
abstract = "Background--Although hydrochlorothiazide (HCTZ) is a well-established first-line antihypertensive in the United States, < 50{\%} of HCTZ treated patients achieve blood pressure (BP) control. Thus, identifying biomarkers that could predict the BP response to HCTZ is critically important. In this study, we utilized metabolomics, genomics, and lipidomics to identify novel pathways and biomarkers associated with HCTZ BP response. Methods and Results--First, we conducted a pathway analysis for 13 metabolites we recently identified to be significantly associated with HCTZ BP response. From this analysis, we found the sphingolipid metabolic pathway as the most significant pathway (P=5.8E-05). Testing 78 variants, within 14 genes involved in the sphingolipid metabolic canonical pathway, with the BP response to HCTZ identified variant rs6078905, within the SPTLC3 gene, as a novel biomarker significantly associated with the BP response to HCTZ in whites (n=228). We found that rs6078905 C-allele carriers had a better BP response to HCTZ versus noncarriers (ΔSBP/ΔDBP: -11.4/-6.9 versus -6.8/-3.5 mm Hg; ΔSBP P=6.7E-04; ΔDBP P=4.8E-04). Additionally, in blacks (n=148), we found genetic signals in the SPTLC3 genomic region significantly associated with the BP response to HCTZ (P < 0.05). Last, we observed that rs6078905 significantly affects the baseline level of 4 sphingomyelins (N24:2, N24:3, N16:1, and N22:1; false discovery rate < 0.05), from which N24:2 sphingomyelin has a significant correlation with both HCTZ DBP-response (r =-0.42; P=7E-03) and SBP-response (r=-0.36; P=2E-02). Conclusions--This study provides insight into potential pharmacometabolomic and genetic mechanisms underlying HCTZ BP response and suggests that SPTLC3 is a potential determinant of the BP response to HCTZ.",
keywords = "Blood pressure, Lipid metabolites, Metabolomics, Pharmacogenetics, Thiazide diuretics",
author = "Shahin, {Mohamed H.} and Yan Gong and Frye, {Reginald F.} and Rotroff, {Daniel M.} and Beitelshees, {Amber L.} and Baillie, {Rebecca A.} and Chapman, {Arlene B.} and Gums, {John G.} and Turner, {Stephen T} and Eric Boerwinkle and Alison Motsinger-Reif and Oliver Fiehn and Cooper-DeHoff, {Rhonda M.} and Xianlin Han and Rima Kaddurah-Daouk and Johnson, {Julie A.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1161/JAHA.117.006656",
language = "English (US)",
volume = "7",
journal = "Journal of the American Heart Association",
issn = "2047-9980",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Sphingolipid metabolic pathway impacts thiazide diuretics blood pressure response

T2 - Insights from genomics, metabolomics, and lipidomics

AU - Shahin, Mohamed H.

AU - Gong, Yan

AU - Frye, Reginald F.

AU - Rotroff, Daniel M.

AU - Beitelshees, Amber L.

AU - Baillie, Rebecca A.

AU - Chapman, Arlene B.

AU - Gums, John G.

AU - Turner, Stephen T

AU - Boerwinkle, Eric

AU - Motsinger-Reif, Alison

AU - Fiehn, Oliver

AU - Cooper-DeHoff, Rhonda M.

AU - Han, Xianlin

AU - Kaddurah-Daouk, Rima

AU - Johnson, Julie A.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background--Although hydrochlorothiazide (HCTZ) is a well-established first-line antihypertensive in the United States, < 50% of HCTZ treated patients achieve blood pressure (BP) control. Thus, identifying biomarkers that could predict the BP response to HCTZ is critically important. In this study, we utilized metabolomics, genomics, and lipidomics to identify novel pathways and biomarkers associated with HCTZ BP response. Methods and Results--First, we conducted a pathway analysis for 13 metabolites we recently identified to be significantly associated with HCTZ BP response. From this analysis, we found the sphingolipid metabolic pathway as the most significant pathway (P=5.8E-05). Testing 78 variants, within 14 genes involved in the sphingolipid metabolic canonical pathway, with the BP response to HCTZ identified variant rs6078905, within the SPTLC3 gene, as a novel biomarker significantly associated with the BP response to HCTZ in whites (n=228). We found that rs6078905 C-allele carriers had a better BP response to HCTZ versus noncarriers (ΔSBP/ΔDBP: -11.4/-6.9 versus -6.8/-3.5 mm Hg; ΔSBP P=6.7E-04; ΔDBP P=4.8E-04). Additionally, in blacks (n=148), we found genetic signals in the SPTLC3 genomic region significantly associated with the BP response to HCTZ (P < 0.05). Last, we observed that rs6078905 significantly affects the baseline level of 4 sphingomyelins (N24:2, N24:3, N16:1, and N22:1; false discovery rate < 0.05), from which N24:2 sphingomyelin has a significant correlation with both HCTZ DBP-response (r =-0.42; P=7E-03) and SBP-response (r=-0.36; P=2E-02). Conclusions--This study provides insight into potential pharmacometabolomic and genetic mechanisms underlying HCTZ BP response and suggests that SPTLC3 is a potential determinant of the BP response to HCTZ.

AB - Background--Although hydrochlorothiazide (HCTZ) is a well-established first-line antihypertensive in the United States, < 50% of HCTZ treated patients achieve blood pressure (BP) control. Thus, identifying biomarkers that could predict the BP response to HCTZ is critically important. In this study, we utilized metabolomics, genomics, and lipidomics to identify novel pathways and biomarkers associated with HCTZ BP response. Methods and Results--First, we conducted a pathway analysis for 13 metabolites we recently identified to be significantly associated with HCTZ BP response. From this analysis, we found the sphingolipid metabolic pathway as the most significant pathway (P=5.8E-05). Testing 78 variants, within 14 genes involved in the sphingolipid metabolic canonical pathway, with the BP response to HCTZ identified variant rs6078905, within the SPTLC3 gene, as a novel biomarker significantly associated with the BP response to HCTZ in whites (n=228). We found that rs6078905 C-allele carriers had a better BP response to HCTZ versus noncarriers (ΔSBP/ΔDBP: -11.4/-6.9 versus -6.8/-3.5 mm Hg; ΔSBP P=6.7E-04; ΔDBP P=4.8E-04). Additionally, in blacks (n=148), we found genetic signals in the SPTLC3 genomic region significantly associated with the BP response to HCTZ (P < 0.05). Last, we observed that rs6078905 significantly affects the baseline level of 4 sphingomyelins (N24:2, N24:3, N16:1, and N22:1; false discovery rate < 0.05), from which N24:2 sphingomyelin has a significant correlation with both HCTZ DBP-response (r =-0.42; P=7E-03) and SBP-response (r=-0.36; P=2E-02). Conclusions--This study provides insight into potential pharmacometabolomic and genetic mechanisms underlying HCTZ BP response and suggests that SPTLC3 is a potential determinant of the BP response to HCTZ.

KW - Blood pressure

KW - Lipid metabolites

KW - Metabolomics

KW - Pharmacogenetics

KW - Thiazide diuretics

UR - http://www.scopus.com/inward/record.url?scp=85040526567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040526567&partnerID=8YFLogxK

U2 - 10.1161/JAHA.117.006656

DO - 10.1161/JAHA.117.006656

M3 - Article

VL - 7

JO - Journal of the American Heart Association

JF - Journal of the American Heart Association

SN - 2047-9980

IS - 1

M1 - e006656

ER -